Vanguard Global Advisers
MAIA icon

Vanguard Global Advisers’s MAIA Biotechnology MAIA Stock Holding History

Vanguard Global Advisers’s Portfolio MAIA Stock Details MAIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Hold
11,401
– – ﹤0.01% 3384
2026
Q1 		$16K Buy
+11,401
New +$21K ﹤0.01% 3380

Other funds holding MAIA

SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CWM
Centric Wealth Management Chicago, Illinois $643M AUM 21% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Global Advisers's MAIA Position: Q2 2026 in Review

Vanguard Global Advisers held its MAIA Biotechnology (MAIA) position steady in Q2 2026 at 11,401 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3384.

Vanguard Global Advisers first reported a position in MAIA in Q1 2026 and has held it in 2 quarters since. 35 funds tracked by Wall St. Rank hold MAIA as of Q2 2026.

  • Vanguard Global Advisers held 11,401 shares of MAIA Biotechnology worth $16.4K as of Q2 2026.
  • Vanguard Global Advisers left its MAIA Biotechnology share count unchanged in Q2 2026.
  • MAIA Biotechnology made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q2 2026, its #3384 holding.
  • Vanguard Global Advisers first reported a position in MAIA Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 35 funds tracked by Wall St. Rank held MAIA Biotechnology as of Q2 2026.

Based on Vanguard Global Advisers's 13F filing for Q2 2026, filed 13 Aug 2026.